Hipertensión pulmonar (I). Hipertensión arterial pulmonar

  1. Cadenas Menéndez, S.
  2. Martín Moreiras, J.
  3. Álvarez Vega, P.
  4. González Calle, D.
  5. Oterino Manzanas, A.
  6. Escribano Subias, P.
  7. Sánchez Fernández, P.L.
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2017

Serie: 12

Número: 45

Páginas: 2655-2673

Tipo: Artículo

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2017.11.003 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen La hipertensión arterial pulmonar (HAP) es una enfermedad vascular pulmonar, que se define en el cateterismo cardíaco derecho, una vez descartadas las principales causas de hipertensión pulmonar precapilar, especialmente enfermedad respiratoria y enfermedad tromboembólica crónica. El estudio de un paciente con HP se realiza a través de un algoritmo en el que se van descartando, por orden de frecuencia, las causas más comunes de HP, cardíacas y respiratorias. Finalmente, si existe sospecha de HAP, se debe realizar un cateterismo cardíaco derecho diagnóstico, además de solicitar los estudios pertinentes para valorar la presencia de alguna de las condiciones asociadas a este diagnóstico: colagenosis, infección por el VIH, cardiopatía congénita e hipertensión portal. En los últimos años se han producido grandes avances en el manejo de los pacientes con HAP, gracias a la aparición de nuevos fármacos y a su utilización en combinación, mediante una estrategia estructurada y dirigida por objetivos.

Referencias bibliográficas

  • Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT. Eur Heart J. 2016;37:67-119.
  • Escribano-Subias P, Blanco I, López-Meseguer M, López-Guarch CJ, Roman A, Morales P. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40: 596-603.
  • Barberá JA, Román A, Gómez Sánchez MA, Blanco I, Otero R, López Reyes R. Diagnóstico y tratamiento de la hipertensión pulmonar. Normativa SEPAR 70;2017:11. 2017.
  • Van Wolferen SA, Marcus JT, Boonstra A, Marques KMJ, Bronzwaer JGF, Spreeuwenberg MD. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28:1250-57.
  • Swift AJ, Rajaram S, Campbell MJ, Hurdman J, Thomas S, Capener D. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2014;7:100-6.
  • Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel ER, Vogel-Claussen J, Turkbey E B, Williams R. Normal values for cardiovascular magnetic resonance in adults and children. J Cardiovasc Magn Reson. 2015;17:29.
  • Subias; SEC Working Group for ESC/ERS 2015 Guidelines for Diagnosis and Treatment of Pulmonary Hypertension; Expert Reviewers for ESC/ERS 2015 Guidelines for Diagnosis and Treatment of Pulmonary Hypertension; SEC Guidelines Committee. Comments on the 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol (Engl Ed). 2016;69:102-8.
  • Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium : channel blockers on survival in primary pulmonary hypertension [see com-ments]. N Engl J Med. 1992;327:76-81.
  • Galié N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hyperten-sion. Am J Cardiol. 1995;75:55A-62A.
  • Galié N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, doubleblind, placebo controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-9.
  • Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet. 2001;358:1119-23.
  • Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
  • Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-9.
  • Galiè N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer GMB. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093-100.
  • Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809-18.
  • Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P. (2015). Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015;46(6):1711-20.
  • Ghofrani HA, Voswinckel R, Reichenberger F, Olschewski H, Haredza P, Karadas B. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase ; 5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004;44:1488-96.
  • Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D. The Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-57.
  • Sastry BKS, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sidenafil in primary pulmonary hypertension: a randomized, placebo controlled, doubleblind, crossover study. J Am Coll Cardiol. 2004;43:1149-53.
  • Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Søndergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo controlled, double-blinded trial. Eur Heart J. 2010;31:1124-31.
  • Singh T, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebocontrolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1–851.e5.
  • Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894-903.
  • Ghofrani HA, Galiè N, Grimminger F, Grunig E, Humbert M, Jing ZC. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330-40.
  • Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [see com-ments]. N Engl J Med. 1996;334:296-302.
  • Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial [see comments]. Ann Intern Med. 2000;132:425-34.
  • Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-91.
  • Sitbon O, Humbert M, Nunes H, Parent F, García G, Herve P. Long term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40: 780-8.
  • McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106: 1477-82.
  • Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 2002;347:322-9.
  • Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo controlled trial. Am J Respir Crit Care Med. 2002; 165:800-4.
  • Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open label, 12-week trial. Chest. 2006;129:683-8.
  • Sitbon O, Manes A, Jaïs X, Pallazini M, Humbert M, Presotto L. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol. 2007;49:1-5.
  • McLaughlin VV, Channick R, Chin KM, Frey A, Gaine S, Ghofrani A. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J Am Coll Cardiol. 2015; 65SupplA:A380.
  • Galiè N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near dead to multiple clinical trial meta-analyses. Eur Heart J. 2010;31:2080-6.
  • Galiè N, Barbera JA, Frost A, Ghofrani A, Hoeper M, Mc Laughlin VV. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New Engl J Med. 2015;379:834-44.
  • Sitbon O, Jaïs X, Savale L, Cottin V, Bergot E, Macari EA. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014 43:1691-7.
  • Coghlan JG, Denton CP, Gruenig E, Bonderman D, Distler O, Khanna D. Evidence based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340-9.
  • Herve P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O. Pulmonary vascular disorders in portal hypertension. Eur Res J. 1998; 11(5):1153-66.
  • Galié N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, doubleblind, placebo controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-9.
  • Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46:65-9.
  • Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V. Pulmonary hypertension in chronic lung diseases. Journal of the American College of Cardiology. 2013;62(25):D109-D116.
  • King TE Jr, Brown KK, Raghu G, Du Bois RM, Lynch DA, Martínez F. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92-9.
  • Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR. Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan A Parallel, Randomized Trial. Ann Inter Med. 2013;158(9):641-9.
  • Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42(6):1622-32.
  • Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014 Dec 9;130(24):2189-208.
Fuente de los datos: Dialnet